Emerging Therapies

Alpelisib First Drug to Improve Outcomes in Advanced Breast Cancer with PIK3CA Mutation

Phoebe Starr

December 2018, Vol 9, No 4 - Breast Cancer, Emerging Therapies

Munich, Germany—Recent results with the investigational targeted therapy alpelisib, a PI3K inhibitor, showed impressive clinical benefits. Adding alpelisib to fulvestrant (Faslodex) extended progression-free survival (PFS) compared with endocrine therapy alone in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer characterized by a PIK3CA mutation, according to the results of the SOLAR-1 trial presented at the ESMO 2018 Congress. [ Read More ]

Targeted Therapy Has Significant Activity as Second-Line Treatment of Cholangiocarcinoma with FGFR Mutations

Wayne Kuznar

December 2018, Vol 9, No 4 - Emerging Therapies

Munich, Germany—Treatment options are few for patients with cholangiocarcinoma whose disease progresses while receiving first-line treatment with gemcitabine (Gemzar) and cisplatin (Platinol), with no established second-line regimen. The median overall survival (OS) is 7.2 months and the median progression-free survival (PFS) is 3.2 months in the second-line setting. [ Read More ]

TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition

Phoebe Starr

October 2018, Vol 9, No 3 - Emerging Therapies

Chicago, IL—A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a pre­liminary phase 1b clinical trial. The addition of CMP-001 to pembrolizu­mab was well-tolerated, with encouraging antitumor responses in patients with metastatic melanoma that progressed with or after treatment with a PD-1 inhibitor. [ Read More ]

Two New Therapies Active in NSCLC with EGFR/HER2 Exon 20 Mutations

Phoebe Starr

October 2018, Vol 9, No 3 - Emerging Therapies

Toronto, Canada—Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC). At the recent International Association for the Study of Lung Cancer World Conference, attention was focused on new drugs for NSCLC associated with EGFR and HER2 exon 20 insertions or mutations, which account for anywhere from 3% to 7% of all cases of NSCLC. The presence of these genetic alterations is associated with primary resistance to tyrosine kinase inhibitors (TKIs), with response rates below 12%. [ Read More ]